Literature DB >> 12842380

The camptothecins.

Joseph F Pizzolato1, Leonard B Saltz.   

Abstract

Supported by detailed understanding of their mechanism of action, and facilitated by chemical manipulations that have amplified their solubility, the camptothecins have advanced to the forefront of several areas of therapeutic and developmental chemotherapy. Additive and synergistic laboratory interactions with other cytotoxic drugs have been exploited to allow development of camptothecin-based multidrug regimens, which are showing important activity in several malignancies. Topotecan and irinotecan are already in widespread use in clinical practice, and newer agents with promising preclinical activity are in various stages of clinical assessment. As knowledge of molecular and biochemical mechanisms of action and resistance continues to expand, newer and better camptothecin-based strategies for treatment of malignant disease are likely to evolve.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842380     DOI: 10.1016/S0140-6736(03)13780-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  77 in total

1.  3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells.

Authors:  Stefan T Yohe; Victoria L M Herrera; Yolonda L Colson; Mark W Grinstaff
Journal:  J Control Release       Date:  2012-06-06       Impact factor: 9.776

2.  Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.

Authors:  Chunyan Liu; Shaoyu Zhou; Shahnaz Begum; David Sidransky; William H Westra; Malcolm Brock; Joseph A Califano
Journal:  Lung Cancer       Date:  2006-11-21       Impact factor: 5.705

3.  Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.

Authors:  Katerina Shulman; Ilana Cohen; Ofra Barnett-Griness; Abraham Kuten; Stephen B Gruber; Flavio Lejbkowicz; Gad Rennert
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

4.  Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.

Authors:  Syed Ahmad; Mark A Hughes; Li-An Yeh; John E Scott
Journal:  J Biomol Screen       Date:  2012-04-24

5.  Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.

Authors:  Changsuk Moon; Weiqiang Zhang; Aixia Ren; Kavisha Arora; Chandrima Sinha; Sunitha Yarlagadda; Koryse Woodrooffe; John D Schuetz; Koteswara Rao Valasani; Hugo R de Jonge; Shiva Kumar Shanmukhappa; Mohamed Tarek M Shata; Randal K Buddington; Kaushik Parthasarathi; Anjaparavanda P Naren
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

6.  In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

Authors:  Roger Gilabert-Oriol; Lina Chernov; Malathi Anantha; Wieslawa H Dragowska; Marcel B Bally
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

7.  Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.

Authors:  Gaofei Xu; Changying Shi; Dandan Guo; Lili Wang; Yun Ling; Xiaobing Han; Juntao Luo
Journal:  Acta Biomater       Date:  2015-04-22       Impact factor: 8.947

8.  Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I.

Authors:  Marc C Rideout; Amy C Raymond; Alex B Burgin
Journal:  Nucleic Acids Res       Date:  2004-08-27       Impact factor: 16.971

9.  Gene interactions in the DNA damage-response pathway identified by genome-wide RNA-interference analysis of synthetic lethality.

Authors:  Gijs van Haaften; Nadine L Vastenhouw; Ellen A A Nollen; Ronald H A Plasterk; Marcel Tijsterman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

10.  Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment.

Authors:  Yiduo Hu; Xincheng Lu; Guangjin Zhou; Ellen L Barnes; Guangbin Luo
Journal:  Mol Biol Cell       Date:  2008-11-05       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.